Skip to main content

Bendroflumethiazide / nadolol Side Effects

Medically reviewed by Drugs.com. Last updated on May 4, 2023.

Applies to bendroflumethiazide / nadolol: oral tablet.

Warning

Oral route (Tablet)

Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. The dosage should be gradually reduced over 1 to 2 weeks, and the patient should be carefully monitored when discontinuing chronic therapy, particularly in patients with ischemic heart disease. If angina markedly worsens or acute coronary insufficiency develops, nadolol should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice.

Serious side effects

Along with its needed effects, bendroflumethiazide/nadolol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking bendroflumethiazide / nadolol:

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking bendroflumethiazide / nadolol:

Symptoms of overdose

Other side effects

Some side effects of bendroflumethiazide / nadolol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to bendroflumethiazide / nadolol: oral tablet.

Cardiovascular

Bendroflumethiazide:

Frequency not reported: Necrotizing angiitis, vasculitis, orthostatic hypotension

Nadolol:

Common (1% to 10%): Heart rate less than 40 beats per minute (bpm), symptoms of peripheral vascular insufficiency, cardiac failure, hypotension, rhythm/conduction disturbances

Frequency not reported: Heart rate less than 60 bpm, first degree heart block, third degree heart block[Ref]

Nervous system

Bendroflumethiazide:

Frequency not reported: Dizziness, vertigo, paresthesia, headache

Nadolol:

Common (1% to 10%): Dizziness/fatigue

Uncommon (0.1% to 1%): Paresthesias, sedation, headache, tinnitus, slurred speech[Ref]

Gastrointestinal

Bendroflumethiazide:

Frequency not reported: Nausea, vomiting, cramping, diarrhea, constipation, gastric irritation, abdominal bloating, sialadenitis, pancreatitis

Nadolol:

Uncommon (0.1% to 1%): Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, bloating, flatulence, dry mouth[Ref]

Dermatologic

Bendroflumethiazide:

Frequency not reported: Purpura, exfoliative dermatitis, pruritus, ecchymosis, urticaria, cutaneous vasculitis, photosensitivity, rash

Nadolol:

Uncommon (0.1% to 1%): Rash, pruritus, dry skin, sweating, facial swelling

Frequency not reported: Reversible alopecia[Ref]

Respiratory

Bendroflumethiazide:

Frequency not reported: Respiratory distress, pneumonitis

Nadolol:

Uncommon (0.1% to 1%): Bronchospasm, cough, nasal stuffiness[Ref]

Metabolic

Bendroflumethiazide:

Frequency not reported: Anorexia, hyperglycemia, metabolic acidosis, hyperuricemia

Nadolol:

Uncommon (0.1% to 1%): Anorexia, weight gain[Ref]

Ocular

Bendroflumethiazide:

Frequency not reported: Xanthopsia, transient blurred vision

Nadolol:

Uncommon (0.1% to 1%): Dry eyes, blurred vision[Ref]

Psychiatric

Bendroflumethiazide:

Frequency not reported: Restlessness

Nadolol:

Uncommon (0.1% to 1%): Change in behavior, impotence or decreased libido[Ref]

Hematologic

Bendroflumethiazide:

Frequency not reported: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia[Ref]

Hepatic

Bendroflumethiazide:

Frequency not reported: Intrahepatic cholestatic jaundice, hepatitis[Ref]

Immunologic

Bendroflumethiazide:

Frequency not reported: Anaphylactic reactions, allergic glomerulonephritis[Ref]

Other

Bendroflumethiazide:

Frequency not reported: Fever, weakness[Ref]

Genitourinary

Bendroflumethiazide:

Frequency not reported: Glycosuria[Ref]

Musculoskeletal

Bendroflumethiazide:

Frequency not reported: Muscle spasm[Ref]

References

1. Product Information. Corzide 40/5 (bendroflumethiazide-nadolol). Bristol-Myers Squibb.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.